Traws Pharma said U.K. regulators issued a “negative review” of its planned human influenza challenge study, forcing the company to defer a phase 2a trial linked to $20 million in funding. The deferral effectively delays the program’s timeline and the ability to generate human data that typically supports downstream development decisions. For challenge studies, regulatory outcomes can quickly change a company’s capital plan because enrollment and dosing readiness are prerequisites for milestone payments and partner confidence. Traws’ decision to pause the planned trial underscores how tightly regulator timelines can constrain fast-moving infectious-disease development.